SELLAS Life Sciences Group, Inc. (SLS) Insider Trading Activity

NASDAQ$2.2
Market Cap
$231.89M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
255 of 823
Rank in Industry
143 of 464

SLS Insider Trading Activity

SLS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$185,406
4
100
Sells
$0
0
0

Related Transactions

Kalin Katherine Bachdirector
2
$136,806
0
$0
$136,806
Wasman Janedirector
1
$33,800
0
$0
$33,800
VAN NOSTRAND ROBERT Ldirector
1
$14,800
0
$0
$14,800

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Insider Activity of SELLAS Life Sciences Group, Inc.

Over the last 12 months, insiders at SELLAS Life Sciences Group, Inc. have bought $185,406 and sold $0 worth of SELLAS Life Sciences Group, Inc. stock.

On average, over the past 5 years, insiders at SELLAS Life Sciences Group, Inc. have bought $185,406 and sold $22,757 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Kalin Katherine Bach (director) — $136,806. Wasman Jane (director) — $33,800. VAN NOSTRAND ROBERT L (director) — $14,800.

The last purchase of 63,400 shares for transaction amount of $100,806 was made by Kalin Katherine Bach (director) on 2025‑11‑19.

List of Insider Buy and Sell Transactions, SELLAS Life Sciences Group, Inc.

2025-11-19PurchaseKalin Katherine Bachdirector
63,400
0.0629%
$1.59
$100,806
+4.11%
2025-06-12PurchaseVAN NOSTRAND ROBERT Ldirector
10,000
0.009%
$1.48
$14,800
+7.88%
2025-05-30PurchaseWasman Janedirector
20,000
0.0198%
$1.69
$33,800
+3.22%
2025-05-22PurchaseKalin Katherine Bachdirector
20,000
0.0205%
$1.80
$36,000
+0.57%
2022-12-05SaleStergiou Angelos M.President and CEO
6,494
0.0347%
$2.61
$16,938
-37.30%
2022-12-05SaleWOOD BARBARA AEVP, Gen. Counsel, Corp. Sec.
2,153
0.0114%
$2.59
$5,576
-37.30%
2022-12-05SaleBurns John ThomasSenior VP, Finance & CAO
1,159
0.0061%
$2.59
$3,002
-37.30%
2021-12-02SaleStergiou Angelos M.President and CEO
2,120
0.0133%
$6.25
$13,252
-51.09%
2021-12-02SaleWOOD BARBARA AEVP, Gen. Counsel, Corp. Sec.
847
0.0053%
$6.25
$5,298
-51.09%
2021-12-02SaleBurns John ThomasVP, Finance & Corp Controller
231
0.0014%
$6.27
$1,448
-51.09%
2018-12-31SaleStergiou Angelos M.President and CEO
23,277
0.1061%
$1.25
$29,189
-86.59%
2017-06-20SaleNisi Rudolphdirector
500
0.0013%
$0.55
$273
-50.00%
2017-02-08SaleHudson Bay Capital Management LP10 percent owner
2.36M
9.0582%
$0.84
$1.99M
-50.00%
2014-02-12SaleChin Richarddirector
187,500
0.1611%
$4.33
$812,438
-48.39%
2014-02-07PurchaseNisi Rudolphdirector
20,000
0.0172%
$4.94
$98,742
-53.96%
2014-02-03SaleGALLIKER STEPHEN Sdirector
300,000
0.2555%
$4.18
$1.25M
-45.97%
2014-01-30SaleSCHWARTZ MARK W.EVP & Chief Operating Officer
100,000
0.0885%
$5.57
$556,500
-57.67%
2014-01-30SaleHillsberg Sanforddirector
250,000
0.2151%
$5.41
$1.35M
-57.67%
2014-01-30SaleChin Richarddirector
75,000
0.0666%
$5.58
$418,755
-57.67%
2014-01-29SaleNisi Rudolphdirector
250,000
0.2151%
$5.28
$1.32M
-56.63%
Total: 100
*Gray background shows transactions not older than one year

SLS Institutional Investors: Active Positions

Increased Positions52+75.36%9M+33.74%
Decreased Positions23-33.33%3M-10.56%
New Positions22New1MNew
Sold Out Positions5Sold Out165,879Sold Out
Total Postitions98+42.03%33M+23.18%

SLS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$13,885.004.82%6.84M+185,106+2.78%2025-09-30
Anson Funds Management Lp$12,247.004.25%6.03M+6M+2,093.8%2025-09-30
Blackrock, Inc.$11,544.004.01%5.69M+1M+23.89%2025-09-30
Marshall Wace, Llp$4,787.001.66%2.36M-357,490-13.16%2025-09-30
Geode Capital Management, Llc$4,597.001.6%2.26M+63,956+2.91%2025-09-30
State Street Corp$2,763.000.96%1.36M+248,209+22.31%2025-09-30
Morgan Stanley$2,141.000.74%1.05M-29,687-2.74%2025-09-30
Nuveen, Llc$2,026.000.7%997,910+26,581+2.74%2025-09-30
Susquehanna International Group, Llp$1,753.000.61%863,575-626,097-42.03%2025-09-30
Northern Trust Corp$1,484.000.52%731,175+32,682+4.68%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.